JournalTOCs

Expert Opinion on Investigational Drugs
Journal Prestige (SJR): 1.166

Citation Impact (citeScore): 3
Number of Followers: 17

Hybrid journal * Containing 5 Open Access article(s) in this issue *
ISSN (Print) 1354-3784 - ISSN (Online) 1744-7658
Published by Taylor and Francis

[2648 journals]

Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2
receptor antagonist: report of the first-in-human single- and
multiple-dose escalation trials in healthy Chinese subjects
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Xiaojiao Li, Qianqian Li, Tianliang Ji, Hong Zhang, Jingrui Liu, Min Wu, Hong Chen, Jinfeng Lou, Chengjiao Liu, Zhongnan Xu, Yanhua Ding
  Pages: 1 - 8
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-05-18T07:19:29Z
  DOI: 10.1080/13543784.2022.2078192
Adenosine pathway inhibitors: novel investigational agents for the
treatment of metastatic breast cancer
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Alessandro Rizzo, Raffaella Massafra, Annarita Fanizzi, Lucia Rinaldi, Antonio Cusmai, Agnese Latorre, Gian Maria Zaccaria, Maria Ronchi, Michele Telegrafo, Gennaro Gadaleta-Caldarola, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
  Pages: 1 - 7
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-05-18T07:19:09Z
  DOI: 10.1080/13543784.2022.2078191
Investigational drugs for ischemic stroke: what’s in the clinical
development pipeline for acute phase and prevention'
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Maria Giulia Mosconi, Maurizio Paciaroni, Walter Ageno
  Pages: 1 - 23
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-05-13T07:15:39Z
  DOI: 10.1080/13543784.2022.2072725
Investigational drugs for immune thrombocytopenia
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Drew Provan, Adrian C Newland
  Pages: 1 - 13
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-05-11T07:19:46Z
  DOI: 10.1080/13543784.2022.2075340
Novel immunotherapy combinations in clinical trials for hepatocellular
carcinoma: will they shape the future treatment landscape'
Open Access Article
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Olabisi Ogunbiyi, Coskun O. Demirtas, Alessandra Gennari, Alessio Cortellini, Rohini Sharma, David James Pinato
  Pages: 1 - 11
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-05-06T12:06:51Z
  DOI: 10.1080/13543784.2022.2072726
PARP inhibitors as single agents and in combination therapy: the most
promising treatment strategies in clinical trials for BRCA-mutant ovarian
and triple-negative breast cancers
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Linjie Luo, Khandan Keyomarsi
  Pages: 1 - 25
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-05-03T03:14:33Z
  DOI: 10.1080/13543784.2022.2067527
Clinical development of antibody-drug conjugates in triple negative breast
cancer: can we jump higher'
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Dimitrios Zardavas
  Pages: 1 - 12
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-05-02T03:48:59Z
  DOI: 10.1080/13543784.2022.2070064
Heart failure with preserved ejection fraction: key stumbling blocks for
experimental drugs in clinical trials
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Amanda Lloji, Jayakumar Sreenivasan, Joel Novograd, Wilbert S. Aronow, Stephen Pan, Gregg M. Lanier
  Pages: 1 - 12
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-04-27T11:38:17Z
  DOI: 10.1080/13543784.2022.2069009
A randomized, open-label, single-dose, two-cycle crossover study to
evaluate the bioequivalence and safety of lenvatinib and Lenvima® in
Chinese healthy subjects
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Zhongnan Xu, Yanli Wang, Guangwen Liu, Jiahui Chen, Wanhua Wang, Yang Cheng, Qing Ren, Yingzi Cui, Wei Yang, Zhengzhi Liu, Xuesong Chen, Jinling Xue, Tianying Chang, Xinyao Qu, Shuang Yu, Yannan Zhou, Kaibo Xu, Zhengjie Su, Qiaohuan Deng, Yicheng Zhao, Haimiao Yang
  Pages: 1 - 10
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-04-19T11:19:30Z
  DOI: 10.1080/13543784.2022.2067528
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing
modifier for spinal muscular atrophy (SMA)
Open Access Article
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Theodora Markati, Gemma Fisher, Sithara Ramdas, Laurent Servais
  Pages: 1 - 11
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-04-11T01:08:17Z
  DOI: 10.1080/13543784.2022.2056836
CAR-T cell therapy for triple-negative breast cancer and other solid
tumors: preclinical and clinical progress
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Chiara Corti, Konstantinos Venetis, Elham Sajjadi, Lorenzo Zattoni, Giuseppe Curigliano, Nicola Fusco
  Pages: 1 - 13
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-03-24T08:38:36Z
  DOI: 10.1080/13543784.2022.2054326
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS)
and severe COVID-19: a critical discussion of recent publications
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Jose Garrido-Mesa, Kate Adams, Julio Galvez, Natividad Garrido-Mesa
  Pages: 1 - 8
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-03-23T08:29:43Z
  DOI: 10.1080/13543784.2022.2054325
Tucatinib: an investigational novel therapeutic agent for the treatment of
HER-2 colorectal cancer
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Daniel Ahn, Daniel Walden, Tanios Bekaii-Saab
  Pages: 1 - 5
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-03-17T09:31:57Z
  DOI: 10.1080/13543784.2022.2053107
KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal
diseases
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Hudson D. Stern, Rehan M Hussain
  Pages: 1 - 7
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-03-16T07:50:31Z
  DOI: 10.1080/13543784.2022.2052042
Why does survival of hepatocellular carcinoma patients remain so low'
Key stumbling blocks and questions in preclinical and clinical development
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Margherita Rimini, Nicole Liscia, Valentina Burgio, Andrea Casadei-Gardini
  Pages: 1 - 12
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-03-16T05:17:05Z
  DOI: 10.1080/13543784.2022.2053108
Progress and pitfalls in the use of immunotherapy for patients with triple
negative breast cancer
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Elisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, Armando Santoro, Kevin Punie, Romualdo Barroso, Lazar Popovic, Cinzia Solinas, Marleen Kok, Evandro de Azambuja, Matteo Lambertini
  Pages: 1 - 25
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-03-09T04:10:28Z
  DOI: 10.1080/13543784.2022.2049232
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary
results, key challenges, and clinical potential
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Alessandro Rizzo, Antonio Cusmai, Silvana Acquafredda, Lucia Rinaldi, Gennaro Palmiotti
  Pages: 1 - 4
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-02-18T02:10:18Z
  DOI: 10.1080/13543784.2022.2042252
A randomized, adaptive design, double-blind, 3-arm, parallel study
assessing the pharmacokinetics and safety of AVT02, a high-concentration
(100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD
FIRST)
Open Access Article
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Christopher Wynne, Christian Schwabe, Charlotte Lemech, Heimo Stroissnig, Roshan Dias, Joanna Sobierska, Eric Guenzi, Hendrik Otto, Abid Sattar, Richard Kay, Halimu N. Haliduola, Fausto Berti
  Pages: 1 - 12
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2022-02-10T02:25:59Z
  DOI: 10.1080/13543784.2022.2035359
Immune-based combinations for metastatic triple negative breast cancer in
clinical trials: current knowledge and therapeutic prospects
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, Lucia Lombardi, Alessandro Di Federico, Giovanni Brandi, Gennaro Gadaleta-Caldarola
  Pages: 1 - 9
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2021-12-14T06:51:51Z
  DOI: 10.1080/13543784.2022.2009456
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Alessandro Rizzo, Angela Dalia Ricci
  Pages: 1 - 7
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2021-11-25T02:31:12Z
  DOI: 10.1080/13543784.2022.2008354
A randomized, double-blind, placebo-controlled, single, and multiple
dose-escalation Phase I clinical trial to investigate the safety,
pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel
angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Yue Hu, Hong Zhang, Xiaojiao Li, Jiajia Mai, Lizhi Yang, Jie Yan, Ying Li, Jingchao Sun, Wenjie Xu, Shiying He, Jinfeng Li, Min Wu
  Pages: 1 - 9
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2021-11-08T08:05:02Z
  DOI: 10.1080/13543784.2021.1985464
Latest generation estrogen receptor degraders for the treatment of hormone
receptor-positive breast cancer
Open Access Article
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Ya-Chi Chen, Jiajie Yu, Ciara Metcalfe, Tom De Bruyn, Thomas Gelzleichter, Vikram Malhi, Pablo D. Perez-Moreno, Xiaojing Wang
  Pages: 1 - 15
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2021-10-25T05:54:34Z
  DOI: 10.1080/13543784.2021.1983542
The emerging role of immune checkpoint inhibitors for the treatment of
breast cancer
Open Access Article
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Frederick M. Howard, Dario Villamar, Gong He, Alexander T. Pearson, Rita Nanda
  Pages: 1 - 18
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2021-10-12T03:22:05Z
  DOI: 10.1080/13543784.2022.1986002
Hepatitis D virus (HDV): investigational therapeutic agents in clinical
trials
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Bilal Asif, Christopher Koh
  Pages: 1 - 16
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2021-10-01T08:34:15Z
  DOI: 10.1080/13543784.2021.1977795
Investigational immunomodulatory drugs for enhancement of triple negative
breast cancer (TNBC) immunotherapy: early phase development
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Paolo Tarantino, Gabriele Antonarelli, Liliana Ascione, Giuseppe Curigliano
  Pages: 1 - 15
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2021-09-27T05:54:15Z
  DOI: 10.1080/13543784.2021.1972968
Giant cell arteritis: what is new in the preclinical and early clinical
development pipeline'
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Authors: Patricia Harkins, Richard Conway
  Pages: 1 - 12
  Abstract: .
  
  Citation: Expert Opinion on Investigational Drugs
  PubDate: 2021-06-30T01:36:43Z
  DOI: 10.1080/13543784.2021.1940949